OCS
HEALTHCAREOculis Holding AG
$29.58+1.83 (+6.59%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving OCS Today?
No stock-specific AI insight has been generated for OCS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$16.00$31.33
$29.58
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-2.42
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume264K
Avg Volume (10D)—
Shares Outstanding58.0M
OCS News
21 articles- Insmed (INSM) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational TrialYahoo Finance·May 7, 2026
- TG Therapeutics (TGTX) Q1 Earnings Lag EstimatesYahoo Finance·May 6, 2026
- Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual MeetingGlobeNewswire Inc.·May 5, 2026
- Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingYahoo Finance·May 1, 2026
- Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors?Yahoo Finance·Apr 29, 2026
- Oculis Publishes Invitation to the Annual General MeetingYahoo Finance·Apr 21, 2026
- Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular EdemaYahoo Finance·Apr 20, 2026
- Oculis to Participate in Upcoming Investor ConferencesGlobeNewswire Inc.·Apr 7, 2026
- Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic NeuritisGlobeNewswire Inc.·Mar 31, 2026
- Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic NeuritisGlobeNewswire Inc.·Mar 31, 2026
- Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual MeetingYahoo Finance·Mar 16, 2026
- Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price PullbackYahoo Finance·Mar 8, 2026
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesYahoo Finance·Mar 6, 2026
- Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue EstimatesYahoo Finance·Mar 3, 2026
- Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company UpdateYahoo Finance·Mar 3, 2026
- Oculis Appoints Katie Kazem as Chief Legal OfficerYahoo Finance·Feb 17, 2026
- Oculis Holding (NasdaqGM:OCS) Valuation Check As Privosegtor Wins FDA Breakthrough Therapy StatusYahoo Finance·Jan 12, 2026
- Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic NeuritisYahoo Finance·Jan 11, 2026
- J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ StocksYahoo Finance·Jan 9, 2026
- Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 8, 2026
All 21 articles loaded
Price Data
Open$27.98
Previous Close$27.75
Day High$28.66
Day Low$27.98
52 Week High$31.33
52 Week Low$16.00
52-Week Range
$16.00$31.33
$29.58
Fundamentals
Market Cap$1.7B
P/E Ratio—
EPS$-2.42
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume264K
Avg Volume (10D)—
Shares Outstanding58.0M
About Oculis Holding AG
Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company is headquartered in Zug, Switzerland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—